RA0261

antibody from Oursmab

Targeting: FOLR1 FOLR, FRα

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0261

Provider

Oursmab

Product name

Luveltamab (Biosimilar Reference Antibody) (FOLR1)

Antibody type

Monoclonal

Description

Luveltamab tazevibulin is an antibody-drug conjugate (ADC) developed by Sutro Biopharma. It consists of a humanized monoclonal antibody targeting folate receptor alpha (FR¦Á), conjugated to the cytotoxic payload tazevibulin (a proprietary hemiasterlin derivative) via a cleavable linker. FR¦Á is overexpressed on the surface of several solid tumors. Upon binding, the ADC is internalized, and the linker is cleaved to release tazevibulin, which disrupts microtubule dynamics and induces cell cycle arrest and apoptosis. It is being developed for the treatment of FR¦Á-expressing advanced solid tumors, with a focus on ovarian cancer.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.